États-Unis - anglais - NLM (National Library of Medicine)

biocon biologics inc. - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine-yfgn is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. limitations of use insulin glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis. insulin glargine-yfgn is contraindicated: risk summary published studies with use of insulin glargine products during pregnancy have not reported a clear association with insulin glargine products and adverse developmental outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dosage of 0.2 units/kg/day. overall, the effects of insulin glargine did not generally differ from those observed with regular human insulin (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically r

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Irlande - anglais - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Union européenne - anglais - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insulins and analogues for injection, intermediate-acting - cats; dogs - for the treatment of diabetes mellitus in cats and dogs to achieve reduction of hyperglycaemia and improvement of associated clinical signs.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - insulin human - parenteral liquid/solution/suspension - insulin human active 40.0 iu/ml - endocrine system

Philippines - anglais - FDA (Food And Drug Administration)

ambica international corp.; distributor: gx laboratories, inc. - biphasic isophane insulin human (recombinant dna origin) - suspension for injection (sc) (30% regular insulin human/70% isophane insulin human) - 100iu/ml

Philippines - anglais - FDA (Food And Drug Administration)

ambica international corp.; distributor: the cathay yss distributors co., ltd. - biphasic isophane insulin human (recombinant dna origin) - suspension for injection (sc) (30% regular insulin human/70% isophane insulin human) - 100iu/ml

Philippines - anglais - FDA (Food And Drug Administration)

ambica international corporation; distributor: ambicare pharmaceuticals inc. - biphasic isophane insulin human (recombinant dna origin) - suspension for injection (sc) (30% regular insulin human/70% isophane insulin human) - 100 iu/ml

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - insulin - parenteral liquid/solution/suspension - insulin hormone active 40.0 iu/ml - endocrine system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - insulin deficiency